Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 19/20 | 0.67 |
| ▸ | CTSB | P07858 | 5/20 | 0.67 |
| ▸ | CTSL | P07711 | 2/20 | 0.67 |
| ▸ | CTSS | P25774 | 3/20 | 0.66 |
| ▸ | CTSK | P43235 | 2/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylamine SCHEMBL1335419 | 0.89 | CAPN1 (0.74) | CAPN1CTSBCTSLCTSSCTSK | |
| SCHEMBL1335332 | 0.82 | CAPN1 (0.67) | CAPN1CTSBCTSLCTSSCTSK | |
| SCHEMBL1335335 | 0.82 | CAPN1 (0.67) | CAPN1CTSBCTSLCTSSCTSK | |
| Diethylamine SCHEMBL1335377 | 0.82 | CAPN1 (0.73) | CAPN1CTSBCTSLCTSSCTSK | |
| SCHEMBL24008797 | 0.82 | CAPN1 (0.60) | CAPN1CTSBCTSLCTSSCTSK | |
| SCHEMBL29961554 | 0.82 | CAPN1 (0.60) | CAPN1CTSBCTSLCTSSCTSK | |
| SCHEMBL1335418 | 0.81 | CAPN1 (0.82) | CAPN1CTSBCTSLCTSSCTSK | |
| SCHEMBL1335416 | 0.81 | CAPN1 (0.82) | CAPN1CTSBCTSLCTSSCTSK | |
| SCHEMBL7318624 | 0.80 | CAPN1 (1.00) | CAPN1CTSBCTSLCTSSCTSK | |
| SCHEMBL7318629 | 0.80 | CAPN1 (1.00) | CAPN1CTSBCTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275615-A1 | NOVEL SUBSTITUTED AMIDES, THEIR PREPARATION AND USE | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2011-11-10 | — | — | US | disclosed |
| US-7956093-B2 | Substituted amides, their preparation and use | ABBOTT GMBH & CO. KG (DE) | 2011-06-07 | — | — | US | disclosed |
| US-20080113989-A1 | For example, N-(1-Carbamoyl-1-oxo-3-phenylpropan-2-yl)-2-(E-2-(4-(1-pyrrolidinylmethyl)phenyl)ethen-1-yl)benzamide; calcium channel blockers; cardiovascular disorders; antiarthritic agents; inhibitors of enzymes, especially cysteine proteases such as calpain and cathepsins | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-05-15 | — | — | US | disclosed |
| US-7276500-B2 | Calcium channel blockers; cardiovascular disorders; antiarthritic agents | ABBOTT GMBH & CO. KG (DE) | 2007-10-02 | — | — | US | disclosed |
| US-6753327-B1 | NEURODEGENERATIVE DISORDER OR NEURONAL DAMAGE TREATMENT; INHIBITORS OF CALPAIN OR CATHEPSIN CYSTEINE PROTEASES; ANTIISCHEMIC AGENTS; REPERFUSION INJURIES | ABBOTT GMBH & CO. KG (DE) | 2004-06-22 | — | — | US | disclosed |
| US-20040082569-A1 | Calcium channel blockers; cardiovascular disorders; antiarthritic agents | ABBOTT GMBH & CO., KG | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275615-A1 | NOVEL SUBSTITUTED AMIDES, THEIR PREPARATION AND USE | CBR3, CBR1, HRH4 | CAPN1 3398/4885CTSB 3328/4885CTSL 3780/4885 |
| US-20040082569-A1 | Calcium channel blockers; cardiovascular disorders; antiarthritic agents | CACNA1C, CACNA1E, RYR1 | CAPN1 862/4885CTSB 2425/4885CTSL 1006/4885 |
| US-20080113989-A1 | For example, N-(1-Carbamoyl-1-oxo-3-phenylpropan-2-yl)-2-(E-2-(4-(1-pyrrolidinylmethyl)phenyl)ethen-1-yl)benzamide; calcium channel blockers; cardiovascular disorders; antiarthritic agents; inhibitors of enzymes, especially cysteine proteases such as calpain and cathepsins | CAPN1, CAPNS1, CAPN2 | CAPN1 1/4885CTSB 10/4885CTSL 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.